Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome

NCT06425055 is registered in ClinicalTrials.gov with Enyo Pharma as lead sponsor.

NCT NCT06425055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06425055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome
Lead sponsor
Enyo Pharma
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2024
Completion date
November 20, 2025
Enrollment
26 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome